BE481435A - - Google Patents
Info
- Publication number
- BE481435A BE481435A BE481435DA BE481435A BE 481435 A BE481435 A BE 481435A BE 481435D A BE481435D A BE 481435DA BE 481435 A BE481435 A BE 481435A
- Authority
- BE
- Belgium
- Prior art keywords
- penicillin
- beeswax
- peanut oil
- blood
- injection
- Prior art date
Links
- 229930182555 Penicillin Natural products 0.000 claims description 69
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 69
- 229940049954 penicillin Drugs 0.000 claims description 69
- 239000012166 beeswax Substances 0.000 claims description 40
- 235000013871 bee wax Nutrition 0.000 claims description 37
- 235000019483 Peanut oil Nutrition 0.000 claims description 24
- 239000000312 peanut oil Substances 0.000 claims description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 23
- 239000011575 calcium Substances 0.000 claims description 23
- 229910052791 calcium Inorganic materials 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 13
- 150000002960 penicillins Chemical class 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 5
- 239000007970 homogeneous dispersion Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 32
- 238000002347 injection Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 239000000203 mixture Substances 0.000 description 21
- 239000003981 vehicle Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 244000105624 Arachis hypogaea Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 235000020232 peanut Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical group [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE481435A true BE481435A (https=) |
Family
ID=128392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE481435D BE481435A (https=) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE481435A (https=) |
-
0
- BE BE481435D patent/BE481435A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1968711B2 (fr) | Gel viscoelastique a usage dermatologique | |
| FR2533439A1 (fr) | Nouvelles compositions pharmaceutiques a base de cis-platine-ii-diammino-dichlorure et procede pour les preparer | |
| FR2588189A1 (fr) | Composition pharmaceutique de type a transition de phase liquide-gel | |
| CA2382389C (fr) | Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale | |
| LU82364A1 (fr) | Composition pharmaceutique cicatrisante contenant un agent antifongique/antibacterien et du sucre,et ses applications | |
| FR2573652A1 (fr) | Composition aqueuse de cromoglycate de sodium | |
| CA2443728C (fr) | Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie | |
| BE897221A (fr) | Produits a effet prolonge contenant du suloctidil | |
| EP4499025A1 (fr) | Emulsion comprenant un hydrogel et de la graisse ou un derive de graisse | |
| BE481435A (https=) | ||
| CA1107650A (fr) | Pate de traitement endodontique pour l'obturation canalaire de dents | |
| CA2554870A1 (fr) | Formulation retard solide comprenant de l'acetate de triporeline | |
| CN117797062A (zh) | 一种具有祛痘功效的油珠精华及其制备方法 | |
| JPH01143831A (ja) | 外用液剤 | |
| BE481476A (https=) | ||
| TW200911252A (en) | Aqueous pharmaceutical composition | |
| CN117244027B (zh) | 一种治疗心血管疾病的药物组合物及其制备方法 | |
| FR2618074A1 (fr) | Formulation destinee a etre utilisee en chirurgie de l'oeil | |
| RU2248198C2 (ru) | Препарат противоожоговый | |
| TW201116274A (en) | Pharmaceutical composition | |
| RU2014050C1 (ru) | Офтальмологическое средство и способ его получения | |
| FR2622800A1 (fr) | Procede de preparation d'un produit de lutte contre des affections virales en particulier des affections virales cutaneo-muqueuses,compositions pharmaceutiques et medicaments obtenus a partir de ce procede | |
| BE502265A (https=) | ||
| US574966A (en) | Albert weller and andreas jensen | |
| CH397955A (fr) | Procédé de fabrication d'une préparation corticotropique à action prolongée |